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Atherosclerosis is the leading cause of mortality in developed countries accounting for 
50% of all deaths.  Atherosclerosis develops when macrophages in the artery wall accumulate 
large amounts of cholesterol via uptake of oxidized low density lipoproteins (LDL), causing a 
negative effect on cholesterol metabolism.  Thus, the development of atherosclerosis can be 
inhibited by increasing cholesterol efflux, which can be achieved by activating ATP binding 
cassette (ABC) transporters in macrophages.  In particular, ABCA1 mediates reverse cholesterol 
transport to the liver via high density lipoproteins (HDL) and therefore is an attractive molecular 
target for raising HDL levels and protecting against atherosclerosis.  ABCA1
 
gene expression is 
known to be regulated by various transcription
 
factors, such as liver X receptor (LXR).  LXRs 
are transcription factors that are activated via binding of ligands, which are oxysterols.  Activated 
LXRs bind to promoter regions at specific sequences known as LXR response elements (LXRE) 
and regulate genes for cholesterol metabolism and transport, as well as for lipogenesis.  Synthetic 
LXR ligands might be useful for treatment of atherosclerosis if they did not induce lipogenesis, 
which can lead to an accumulation of cholesterol via activation of steroid response element 
binding protein (SREBP)-1c in the liver.  To develop selective treatments for atherosclerosis, we 
need to understand mechanisms of selective gene regulation.  LXRs occur as two isotypes, 
LXRα (NR1H3) and LXRβ (NR1H2). Both isotypes regulate genes encoding proteins involved 
in cholesterol metabolism and transport, as well as in lipogenesis.  However, knock-out studies 
have shown that LXRβ activation results in more effective gene activation in the periphery, such 
as in macrophages, which can promote cholesterol efflux.  The mechanism of this LXR isotype-
selectivity is poorly understood.  In this document, we will show how protein-protein 
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interactions affect LXR  and LXR  function and explore the mechanism of nuclear export of 
LXR  and LXR .   






1.1 Nuclear Receptors 
1.1.1 Introduction 
Nuclear receptors are a large superfamily of transcription factors that regulate genes 
important to physiological functions such as homeostasis, reproduction, and development in 
target cells (Table 1.1).  Nuclear receptor activity can be modified by binding to ligands, 
typically small biologically active compounds such as hormones and lipids.  A few well known 
nuclear receptor ligands are hormones such as steroids, retinoids, thyroid hormone, and vitamin 
D3.  A large number of nuclear receptors have been identified by amino acid sequence similarity 
to known receptors, but some have no identified natural ligand and are referred to as nuclear 
orphan receptors.  Nuclear receptors are found within the cytoplasm and nucleus of the cell 
where they can directly regulate target genes by binding to a specific sequence on DNA, known 
as the response element, usually found within the promoter region of the target gene.  Each 
response element consists of two half-sites of a consensus sequence which can be oriented as 
direct repeats or indirect repeats which allows nuclear receptors to bind as a monomer, 
homodimer, or heterodimer (Giguere 1999).  The expression of a large number of genes is 
regulated by nuclear receptors.  Many of these regulated genes are associated with major 
diseases such as cancer, diabetes, obesity, and atherosclerosis, which explain why nuclear 
receptors are used as molecular targets of approximately 13% of U.S. Food and Drug 
Administration (FDA) approved drugs (Overington, Al-Lazikani et al. 2006; Simmons 2006).  
Some of the top prescription drugs on the market target a NR including the drugs bicalutamide 
(Casodex), an androgen receptor (AR) ligand used to treat conditions for prostate cancer; 
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Spironolactone (Aldactone), a mineralcorticoid receptor (MR) ligand for heart failure; 
levothyroxine (Sythroid),thyroid receptor (TR) ligand for hypothyroidism; bexarotene  
Table 1.1 Nuclear Receptor involvements in physiology 
Physiological functions Implicated NRs 
Reproduction ER, PR, and AR 
Fetal Development TR, RAR, and PPARδ 
Cardiovascular homeostasis ERα, PR, RAR, TR, PPARγ, and PPARδ 
Skeletal homeostasis ERα, VDR, TR 
Central nervous system homeostasis ER, PR, GR, RAR, TR, PPARδ 
Immunomodulation GR, VDR, RAR, and PPAR 
Hematopoiesis ERβ and RAR 
Inflammation GR, RAR, PPAR, and LXR 
Wound healing PPARα and PPARδ 
Glucose homeostasis ER, GR, and PPAR 
Lipid and cholesterol homeostasis VDR, TR, PPAR, LXR, FXR, CAR, and PXR 
Toxin detoxification CAR and PXR 
(Targretin), an retionoid X receptor(RXR) ligand for skin cancer;  and rosiglitazone (Avandia), a 
peroxisome proliferator-activated receptor (PPAR) ligand used for diabetes.  The search for 
ligands for orphan receptors has become an active research area because of the potential to be 
used as therapeutic targets.  For example, reverse orientation c-erb (Reverbs) and Retinoic acid 
receptor-related orphan receptor (ROR) have been de-orphanized but are still considered to be 
nuclear receptor  due to the discovery of their ligands (Raghuram, Stayrook et al. 2007; Meng, 
McMaster et al. 2008; Rogers, Ying et al. 2008; Kumar, Solt et al. 2010; Wang, Kumar et al. 
2010).    
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1.1.2 Classification and Nomenclature of NRs 
1.1.2.1 Classification 
The nuclear receptors are found across a variety of species.  There are 48 nuclear receptor 
genes that are found within the human genome, 21 within the Drosophila melanogaster genome, 
and 270 within the Caenorhabitis elegans genome (Laudet 1997; Giguere 1999; Maglich, Sluder 
et al. 2001; Robinson-Rechavi, Carpentier et al. 2001).  These nuclear receptors are classified 
into four classes such as Type I Nuclear Receptors, Type II Nuclear Receptors, Type III Nuclear 
Receptors and Type IV Nuclear Receptors based on their ligand and DNA binding 
characteristics.  The Type I NRs are the classic steroid hormone receptors which include the 
androgen receptor (AR), estrogen receptor (ER), glucocorticoid receptor (GR), mineralcorticoid 
receptor (MR), and the progesterone receptor (PR) (Figure 1.1).  Type II NRs are non-steroid 
receptors that heterodimerize with RXR which include farnesoid X receptor (FXR), liver x 
receptor (LXR), peroxisome proliferator-activated receptor (PPAR), retinoid receptor (RAR), 
thyroid hormone receptor (TR), and the vitamin D receptor (VDR).  The Type III and Type IV 
NRs are the orphan nuclear receptors which lacked a known physiological ligand when they 
were identified and can either bind DNA as a monomer or dimer.  Type III NRs are dimeric 
orphan receptors that include hepatocyte nuclear factor 4 (HNF-4), chicken ovalbumin upstream 
promoter (COUP), and germ cell nuclear factor (GCNF).  The Type IV NRs are 
monomeric/tethered orphan receptors that include steroidogenic factor (SF-1), ROR, Reverb, and 
small heterodimeric partner (SHP).   
Although all nuclear receptors regulate gene expression, among the four classes there are 
subtle differences in the biochemical mechanisms.   Nuclear receptors can be found in either the 
cytoplasm or nucleus.  For some receptors (i.e. GR, ER),unliganded nuclear receptors are bound 
to heat shock proteins which makes them unable to activate transcription.  In the presence of 
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their ligand, NRs dissociate from the heat shock protein and are able to homodimerize or 
heterodimerize with RXR, which allows the NRs to pass through the nuclear pores to bind to 
their response elements  that exists as half-sites separated by variable length nucleotide spacers 
between direct or inverted half-site repeats in the genome.  Once the NR binds to DNA, this 
NR/DNA complex then recruits additional proteins which are involved in activating transcription 
of target genes.   
 
Figure 1.1 Human Nuclear Receptors Classes (Olefsky 2001) 
1.1.2.2 Nomenclature 
In the past decade, over 300 genes were identified belonging to the nuclear receptor 
superfamily, leading to the development of a system to identify nuclear receptors by 
classification and nomenclature.  This system became inefficient because there were several 
names for the same gene, and was especially problematic for the orphan receptors since they 
were described by their sequence, not by their function, at the time of their discovery (Enmark 
and Gustafsson 1996).  After being discussed at the Seventh International CBT Symposium on 
“Nuclear Orphan Receptors” in Huddinge, Sweden, in 1995, it was decided that the system had 
Type I Type II 
Type III Type IV 
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to be changed because it was too confusing.  For that reason, four scientists formed together to 
form a committee for the nomenclature of nuclear receptors to incorporate nuclear receptors 
genes already identified, but to be flexible enough to allow newly identified nuclear receptors to 
be added.  In 1999, the new nomenclature was released and it is based on the evolution of the 
two most highly conserved domains of nuclear receptors, which are the DNA binding domain 
and the ligand binding domain, and uses molecular phylogeny to connect and classify all known 
nuclear receptor sequences (Laudet 1999) corresponding to receptor function.  For example, the 
estrogen receptor binds to estrogen, which is a hormone that is involved in reproduction.  Hence, 
the main function of this receptor involves reproductive development.  This system yields six 
subfamilies and 26 groups of receptors.  Each receptor/gene name is denoted by the letters „NR‟ 
and a three digit identifier containing an Arabic number such as l, 2, 3, etc. for the subfamily, a 
capital letter for the group, and another Arabic number for the gene.  The term isoform is used to 
describe the different gene products originating from the same gene due to alternative promoters, 
alternative splicing, or alternative starts of translation.  Isoforms are designated by a lowercase 
letter following the last Arabic number.  All the unusual receptors that contain either the DNA 
binding domain or the ligand binding domain are grouped separately as subfamily 0 (Table 1.2).  
For example, the liver x receptor (LXR) β which belongs to subfamily1, group H, and is the 
second identified in that group, is named NR1H2.  When a manuscript is written dealing with 
NRs, it is recommended that the NR‟s be identified by the official name at least once in the 
Summary and the Introduction of the manuscript. Once the official name is established, (e.g.“ 
this paper describes LXRβ (NR1H2), a member of nuclear receptor superfamily”) then the author 
may use the trivial at this point.  When a new NR sequence is identified, researchers are 




1.1.3 Nuclear Receptor Protein Structure 
Nuclear receptors share a common structural organization which consists of five structural 
domains (A-F) (Krust, Green et al. 1986) (Figure 1.2).  The N-terminal regulatory domain (A/B 
domain) may contain the activation function 1 (AF-1) domain, whose action is independent of 
the presence of ligand (Novac and Heinzel 2004). The transcriptional activation activity of AF-1 
is normally very weak.  The DNA binding domain (DBD, C domain) consists of two zinc fingers 
that bind to the corresponding response element.  The hinge region (D domain) is thought to be a 
flexible region that connects the DBD with the LBD and varies in length between various 
nuclear receptors.  The ligand binding domain (LBD) (E domain) is responsible for ligand 
binding and dimerization of receptor if it is a dimer.  The LBD also interacts with coactivator and 
corepressor proteins usually via LxxLL motifs. The C-terminal domain (F domain) is a region 
that contains the activation function 2 (AF-2) which stimulates transcription once the ligand 
binds. 
The three-dimensional (3D) structure of proteins is obtained through a combination of 
several techniques that consist of x-ray crystallography and nuclear magnetic resonance (NMR) 
spectroscopy.  The 3D structure of a NR DBD was obtained from GR-DBD and ER-DBD using 
NMR spectroscopy (Luisi, Xu et al. 1991; Schwabe, Chapman et al. 1993; Steinmetz, Renaud et 
al. 2001).  So far, structures of NR LBD have been shown for VDR, AR, ER, PPAR, LXR and 
RXR (Wurtz, Bourguet et al. 1996; Uppenberg, Svensson et al. 1998; Norman, Adams et al. 
1999; Färnegårdh, Bonn et al. 2003).  These findings gave insight on the actions of NR such as 
the molecular dynamics of ligand binding, coactivator interaction, and transactivation which 
allowed for the design of synthetic NR ligands to modulate these actions (Renaud and Moras 
2000; Son and Lee 2009).  Recently, the first intact structure of the nuclear receptor on multiple 
domains such as DNA, ligands, and coactivator peptides was described between PPARδ and 
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RXR as a heterodimer bound to DNA while other structural studies focused on isolated DNA  
(Chandra, Huang et al. 2008).  
1.1.4 Coactivators and Corepressors 
 
The functional activity of a NR is not solely regulated by hormones and other endogenous 
lipophilic ligands, because they also form a complex with regulatory proteins including 
corepressors and coactivators.  When these NRs are not bound by ligand, they are complexed 
with corepressors.  These corepressors include receptor interacting protein 140 (RIP140), nuclear 
receptor corepressor (NCoR), and silencing mediator of retinoic acid and thyroid hormone 
receptor (SMRT) which inhibit nuclear receptors transcriptional activation activity often through 
recruitment of histone deacetylases and DNA methyltransferases on a target gene‟s promoter.  
These enzymatic activities promote the association of proteins that are involved in maintaining 
heterochromatin and silenced regions of DNA (Metivier, Leray et al. 2003).  The NR becomes 
activated when bound by ligand, resulting in dissociation of the corepressors and in recruitment 
of coactivators along with other proteins that are responsible for transcription, such as RNA 
polymerase II.  Coactivator recruitment is an important component of NR signaling pathways 
(Nolte, Wisely et al. 1998).  The activities of coactivators include chromatin remodeling and 
modifications of histones including ubiquination, sumoylation, acetylation, methylation, and 
phosphorylation,that allow transcription to occur.  For example, the dynamic performance and 
decision processes of eukaryotic cells are controlled by post-translational modifications, such as 
protein phosphorylation.  Phosphorylation of nuclear receptors can play a major role in their 
regulation and function (Sun, Montana et al. 2007).  Nuclear receptors can be phosphorylated in 
their N-terminal activation domains (AF-1), the DNA binding domain, and the ligand binding  
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Figure 1.2 General structures of NRs (de Lera, Bourguet et al. 2007).   
domain.  Phosphorylation of nuclear receptors plays a role in the recruitment of coactivators and 
transcriptional machinery and therefore activation and/or repression of transcription, as well as in  
nuclear receptor degradation (Rochette-Egly 2003).    
 
1.1.5 Nuclear Export 
A number of the nuclear receptors are known to shuttle between the cytoplasmic and nuclear 
compartments.  Nuclear export of the respective nuclear receptors occurs through nuclear pore 
complexes (NPCs) but all of the mechanisms of export are not known (Mingot, Bohnsack et al. 
2004; Pemberton and Paschal 2005).  Nuclear receptors must localize in the nucleus to perform 
their functions as transcription factors. The intranuclear concentration of most nuclear proteins is 
maintained by a balance of continuous nuclear import and export. Therefore, regulation of both 
nuclear import and export are important regulatory checkpoints for nuclear receptor functions.  
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There is no common pathway for nuclear receptor export; however, nuclear export often occurs 
through karyopherin-mediated mechanisms.  Many nuclear proteins are exported through the 
karyopherin chromosome region maintenance (Crm-1) which binds to leucine-rich nuclear 
export sequences (NES) in the cargo protein and RanGTP (Fornerod, Ohno et al. 1997; Tsay, Lin 
et al. 1999; Lo, Gay et al. 2004).  It has been shown that ER and ligand bound VDR are exported 
via Crm-1(Lee and Bai 2002; Prufer and Barsony 2002; Nonclercq, Journe et al. 2007).  Export 
via Crm-1 can be inhibited by leptomycin B (Kudo, Matsumori et al. 1999).  In addition to Crm-
1, another karyopherin transporting protein from the nucleus, Exportin 7, was identified. 
Exportin 7 binds and exports 14-3-3ζ out of the nucleus (Gorlich and Kutay 1999).  
Interestingly, 14-3-3 has been shown to regulate the trafficking of nuclear receptors such as GR 
and ChREBP (Kino, Souvatzoglou et al. 2003; Sakiyama, Wynn et al. 2008) 
 
Figure 1.3 Schematic of a Model for Directional Nucleocytoplasmic Transport Import or Export 







1.2Liver X Receptors 
Liver X Receptors (LXRs) are ligand-induced transcription factors that belong to the Type II 
nuclear receptor superfamily.  LXR subfamily consists of two subtypes called LXR  (NR1H3) 
and LXR  (NR1H2).  Initially, they were discovered by screening a rat and human liver cDNA 
library and were classified as nuclear orphan receptors since their ligand was unknown (Apfel, 
Benbrook et al. 1994; Song, Kokontis et al. 1994; Willy, Umesono et al. 1995).  The LXR 
proteins each consist of four domains: 1) N-terminal ligand-independent , AF-1 domain, which 
may stimulate transcription in the absence of ligand, 2) DBD, which contains two zinc fingers, 3) 
hinge region 4) LBD, which is required for ligand binding and receptor dimerization, and 4) 
ligand-dependent, AF-2 domain, which stimulates transcription in response to ligand binding.  
Upon ligand activation, both receptors form obligate heterodimers with RXR to regulate 
transcription through binding to LXR response elements (LXRE) in the promoter region of target 
genes (Figure 1.4).  The LXRE consists of two AGGGTCA sites separated by four bases called 
direct repeat-4 (DR-4).   The LXR/RXR interaction is considered a “permissive heterodimer” 
because LXR/RXR interaction may be activated by the ligand of either partner in an independent 
manner (Willy, Umesono et al. 1995).  In the absence of ligands, LXR/RXR heterodimers recruit 
complexes consisting of corepressors (NCoR/SMRT) and prevent transcription (Brendel, 
Schoonjans et al. 2002; Hu, Li et al. 2003; Phelan, Weaver et al. 2008) (Figure 1.3).  Whereas 
when ligand is present, the corepressors dissociate allowing coactivators (SRC1 and p300) to be 
recruited along with other transcriptional machinery (Wiebel, Steffensen et al. 1999).   
LXRs regulate cholesterol transport in the liver and macrophages and under normal 
circumstances prevent atherosclerosis (Repa and Mangelsdorf 2002; Tangirala, Bischoff et al. 
2002; Terasaka, Hiroshima et al. 2003; Crestani, De Fabiani et al. 2004).  Synthetic LXR ligands 
potentially could be used to treat diseases such as atherosclerosis (Terasaka, Hiroshima et al. 
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2003), but their lipogenic effect in the liver causes hypertriglyceridemia, an undesirable side 
effect (Plosch, Kok et al. 2002).   
LXR  and LXR  share ~78% identity of their amino sequences in both their DBD and LBD 
(Ulven, Dalen et al. 2005).  They are activated by oxidized cholesterol derivatives or oxysterols 
such as 22-(R) hydroxycholesterol and 24-(S) hydroxycholesterol, which are naturally occurring, 
and by synthetic ligands T0901317 and GW3965 (Willy, Umesono et al. 1995; Janowski, Willy 
et al. 1996; Peet, Janowski et al. 1998; Urban, Cavazos et al. 2000) (Figure 1. 4).  In contrast to 
oxysterols being able to activate LXRs, geranyl geranyl pyrophosphate, an intermediate of 
cholesterol biosynthesis pathway, inhibits both LXR isoforms by acting as an antagonist.  The 
antagonist is able to inhibit the interaction between LXRs and coactivators (Forman, Ruan et al. 
1997; Gan, Kaplan et al. 2001). 
              
Figure 1.4  The mechanism of transcriptional activity by LXRs (Baranowski 2008).   
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The LXR/RXR interaction has a crystal structure of LXR /RXRβ heterodimer.  It was 
identified that histidine 383, histidine 390, and glutamic acid residues 387 in LXR  act as 
important residues for a strong interaction with glutamic acid 465, glutamic acid 472, alanine 
469,  in RXRβ forming a salt bridge (Svensson, Ostberg et al. 2003).  The RXR subfamily 
includes three isoforms such as RXR α, β, and γ which also have the same amino acids that play 
a role in the stability of the LXR /RXRβ heterodimer.  However, LXRβ has a glutamine and 
 
Figure 1.5  Liver X Receptor natural and synthetic ligands (Zaveri, Murphy et al. 2007) 
leucine at positions that are analogous to LXRα histidine positions 383 and 390.  These 
differences between LXRα and LXRβ protein sequence may play a role in their unique functions. 
LXRs regulate cholesterol transport in the liver, intestine, and macrophages (Repa and 
Mangelsdorf 2002; Tangirala, Bischoff et al. 2002; Terasaka, Hiroshima et al. 2003; Crestani, De 
Fabiani et al. 2004)  by a process referred to as reverse cholesterol transport (RCT).  Although 
LXRα and LXRβ share 78% similarity in amino acid sequence within both the DBD and LBD, 
they do have differences in tissue distribution, gene expression, post-translational modifications, 
and protein-protein interactions.  Specifically, LXR  is abundantly expressed in the liver, 
15 
 
intestine, kidney, spleen, and adipose tissue, whereas LXR  is ubiquitously expressed at lower 
levels (Teboul, Enmark et al. 1995; Willy, Umesono et al. 1995; Repa, Li et al. 2007).   
LXRs exert their function by regulating target genes involved in metabolic pathways by 
binding to DNA sequences in the promoter region of genes (Table 1.3).  Even though both LXRα 
and LXRβ are expressed in liver and macrophages, some genes are selectively activated by 
LXRα or LXRβ.  Under normal circumstances, LXRs induce the expression of cholesterol 7 
alpha-hydroxylase (Cyp7A1) via binding to an LXRE present in the promoter of Cyp7A1,which 
codes for an enzyme that induces the conversion of cholesterol to bile acids then it is removed 
from the body (Lehmann, Kliewer et al. 1997).  However, this induction seems to be species 
specific as LXR suppresses expression of Cyp7A1 in primary human hepatocytes (Chiang, 
Kimmel et al. 2001; Goodwin, Watson et al. 2003).  This repression may be due to the 
interaction between LXR and small heterodimer partner (SHP), because SHP has a known 




 mice failed to induce Cyp7A1 and caused an accumulation of large amounts of 
cholesterol esters in the liver (Peet, Janowski et al. 1998; Alberti, Schuster et al. 2001; Quinet, 
Savio et al. 2006).  Also, it has been shown that mice fed a high- fat diet accumulate more 




than in wild-type LXRβ or LXRβ
 -/- 
mice (Korach-
Andre, Parini et al. 2010).  Both ABCA1 and SREBP-1c expression was less in the liver of 
LXR  
-/-





have shown that LXRβ activation results in more effective gene activation in the periphery, such 
as in macrophages, than in the liver.  These results showed that LXRβ activation did not cause 
hypertriglyceridemia (Schuster, Parini et al. 2002; Lund, Peterson et al. 2006; Quinet, Savio et al. 
2006; Bradley, Hong et al. 2007).  
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Additional studies have shown that LXRs regulate genes in the family of ABC 
transmembrane lipid transporters including ABCA1 (Costet, Luo et al. 2000; Repa, Turley et al. 
2000), ABCG1 (Venkateswaran, Repa et al. 2000; Kennedy, Venkateswaran et al. 2001; Sabol, 
Brewer et al. 2005), ABCG5 and ABCG8 (Repa, Berge et al. 2002; Yu, York et al. 2003).  These 
transporters are responsible for exporting lipids and cholesterol from peripheral tissues to the 
Table 1.3 LXR target genes and their function 
Target Gene Target Tissue Function 
CYP7A1 liver bile acid synthesis 
ABCA1 macrophage, intestine cholesterol efflux 
ABCG5/8 liver, intestine sterol transport 
ABCG1 macrophage cholesterol efflux 
APOE macrophage, adipocyte component of lipoprotein 
LPL liver, macrophage Triglyceride hydrolysis 
FAS liver, adipocyte cholesterol metabolism 
SREBP1C liver, adipocyte, intestine fatty acid synthesis 
LXRα macrophage cholesterol sensor 
 
liver in a process known as reverse cholesterol transport (RCT) (Costet, Luo et al. 2000; Repa, 
Turley et al. 2000; Venkateswaran, Repa et al. 2000; Kennedy, Venkateswaran et al. 2001; 
Sabol, Brewer et al. 2005; Zelcer and Tontonoz 2006).  When ABCG5 and ABCG8 are 
expressed, they lead to decreased cholesterol absorption from the intestinal lumen and increased 
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transport of cholesterol from the liver to the bile duct (Repa, Berge et al. 2002; Yu, York et al. 
2003).  Apolipoproteins serve as cholesterol acceptors in lipoprotein particles and are induced by 
LXRs, such as ApoE (Laffitte, Repa et al. 2001; Mak, Laffitte et al. 2002). 
 LXRα and LXRβ have been shown to undergo differential SUMOylation where LXRβ 
was SUMO1 conjugated by PIAS1, whereas LXRα was SUMO2/3 conjugated by HDAC4 in 
brain astrocytes (Lee, Park et al. 2009).  In addition, LXRα and LXRβ are both phosphoproteins 
(Chen, Pace et al. 1999; Mo, Fang et al. 2002).  Phosphorylation of LXRα affects its function: 
LXRα transcriptional activity decreased upon activation of Protein Kinase C (PKC) in Cos-1, 
HEK293T, and HepG2 cells (Delvecchio, Bilan et al. 2007), and the SREBP-1c promoter was 
inhibited by Protein Kinase A (PKA) through LXRα in the liver (Yamamoto, Shimano et al. 
2007).  Phosphorylation of LXRβ by ALK-1 induces cytoplasmic localization (Mo, Fang et al. 
2002), but no data are available about the functional consequences of phosphorylation of LXRβ 
by either PKA or PKC. In addition, tissue-selective regulation of ABCA1, ABCG1, SREBP-1C, 
and LPL expression by phosphorylated LXRα was shown in macrophages (Torra, Ismaili et al. 
2008).    
The LXRs have several unique protein-protein interactions which may play a role in the 
nonredudant functions of LXRs.  SHP interacts with LXRα in an AF-2 dependent manner 
(Brendel, Schoonjans et al. 2002).  It has been shown that both LXRα and LXRβ interact with 
the C-terminal domain of NCoR. In addition, it was shown that the interaction was isoform 
selective since LXRα has a stronger interaction with NCoR while LXRβ did not suggesting that 
the two isoforms recruit repressors differently (Hu, Li et al. 2003; Phelan, Weaver et al. 2008). 
LXRs are assumed to undergo nuclear export but the export receptor that is responsible is 
unknown.  It has been shown that unliganded and ligand-bound LXRα and LXRβ are slowly 
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exported from the nucleus but while in the presence of the LXR anatagonist, geranyl geranyl 
pyrophosphate (ggPP), there was faster nuclear export of LXRs (Prufer and Boudreaux 2007).   
 Although LXRs have been extensively studied, the mechanism of tissue and LXR-
isotype selectivity is poorly understood.  Taken together these findings indicate a role for LXRs 
in promoting an increased reverse cholesterol transport (RCT), decreased dietary cholesterol 
uptake as well as increased cholesterol efflux.  These features are highly beneficial in preventing 
metabolic disorders but if characterized it might suggest LXRs being used as therapeutic targets.  
1.3 14-3-3 Proteins 
The 14-3-3 proteins are a family of molecules that regulate intracellular signal transduction 
events within all eukaryotic cells.  These 30kDa α-helical molecules consist of seven isotypes (β, 
γ, ε, ζ, δ, η, and ε) in mammals, 15 isoforms in Arabidopsis and two each in Drosophila 
melanogaster and Caenorhabditis elegans (Rittinger, Budman et al. 1999; Fu, Subramanian et al. 
2000; Tzivion, Shen et al. 2001).  14-3-3 proteins are able to form dimers.  These dimeric 14-3-3 
proteins are ubiquitously expressed and play a role in a wide variety of signal transduction 
pathways including, the mitogen activated protein kinase pathway (MAPK) pathway.  In the 
MAPK pathway, Raf links activated cell surface receptors to the classical MAPK, extracellular 
signal-regulated kinase (ERK) 1 and 2, and MAPK/ERK.  In addition to Raf, mitotic 
phosphatase Cdc25C/B regulates entry from G2 into mitosis and apoptosis through the BH3 
domain-only pro-apoptotic protein (Fanger, Widmann et al. 1998; Rittinger, Budman et al. 1999; 
Fu, Subramanian et al. 2000; Tzivion, Shen et al. 2001).  14-3-3 participates in regulating the 
subcellular localization and function of both Raf and Cdc25C/B (Brunet, Kanai et al. 2002).   
14-3-3 regulates cellular processes by affecting the protein‟s localization (Muslin, Tanner et 
al. 1996).   In most cases, 14-3-3 binding sequesters the phosphorylated target protein in a 
particular subcellular compartment, and dephosphorylation of the target protein releases it from 
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14-3-3 and makes it available to signaling pathways.  This mechanism of regulation contributes 
to the nuclear retention of proteins including human telomerase reverse transcriptase (TERT), 
thioredoxin-like protein 2 (Txl-2), and checkpoint kinase (Chk1) (Tang, Suen et al. 1998; 
Seimiya, Sawada et al. 2000; Jiang, Pereira et al. 2003). 
14-3-3 proteins interact with target proteins that are phosphorylated but they can bind to 
those that are not phosphorylated as well.  14-3-3 proteins form homo- and heterodimeric cup-
shaped structures (Liu, Bienkowska et al. 1995; Xiao, Smerdon et al. 1995).  These structures 
allow 14-3-3 proteins to bind to a large number of phosphorylated proteins through one or more 
short phosphoserine/threonine containing sequence motifs in target proteins (Muslin, Tanner et 
al. 1996; Yaffe, Rittinger et al. 1997).  14-3-3 proteins recognize sequences R (S/Ar)XpSXP and 
R X(Ar/S)XpSXP, in which „Ar‟ denotes an aromatic residue (Yaffe, Rittinger et al. 1997).  
However, a few of the 14-3-3 binding peptides have been shown with sequences that deviate 
from these motifs or do not require phosphorylation.  For example, binding of 14-3-3 to proteins 
like R18, a Raf derived peptide  (Fu, Subramanian et al. 2000), and carbohydrate response 
element-binding protein (ChREBP) does not require a phosphorylated residue (Li, Chen et al. 
2008). 
 14-3-3 , also known as stratifin, has been widely studied because of its affiliation with 
cancer (Hermeking 2003).  14-3-3  is a target gene of p53 and upregulation of 14-3-3  leads to 
cell cycle arrest (Hermeking, Lengauer et al. 1997).  Also, it has been shown that 14-3-3  
interacts with members of the nuclear receptor superfamily, the glucocorticoid receptor (GR)  
and the androgen receptor (AR) (Widen, Zilliacus et al. 2000; Quayle and Sadar 2007).  14-3-3  
was shown to increase the transcriptional activity of AR in the absence of ligand and act as a 
negative regulator of GR  signaling (Widen, Zilliacus et al. 2000; Kino, Souvatzoglou et al. 
2003).  These data together led us to hypothesize that interaction of 14-3-3  with LXRs may 
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play a role in functions of LXRs.  Therefore, we explored whether 14-3-3  interacts with and 
affects the functions of LXR  and LXR . 
1.4 Cell Lines 
1.4.1 HepG2 Cells 
HepG2 cells are a human liver carcinoma cell line that was derived from a 15 year old 
Caucasian American male and have an epithelial morphology.  HepG2 cells are used routinely 
for a variety of biochemical and cell biological studies which include of liver specific metabolic 
functions such as cholesterol synthesis, cholesterol transport, cholesterol uptake and cholesterol 
secretion (Erickson and Fielding 1986; Javitt 1990; Pandak, Stravitz et al. 1996; Izem, Rassart et 
al. 1998).  HepG2 cells can be propagated in cell culture in contrast to primary liver cells which 
cannot. 
1.4.2 HEK 293 Cells 
 
 Human Embryonic Kidney 293 cells are a cell line that was derived from an aborted fetus 
then transformed by adenovirus 5 DNA.  The number 293 was originated from Frank Graham‟s 




HEK 293 cells are very easy to grow and transfect and have been widely used in 
cell biology research. Also, they are used by the biotechnology industry to produce therapeutic 
proteins and viruses for gene therapy.   
1.4.3 Cos-7 Cells  
 
 Cos (CV-1 (simian) in origin, and carrying the SV40 genetic material) is a cell line that 
was derived from kidney cells of the African green monkey which has a form of the SV40 
genome obtained by using a constitutively active CV-1 (Jensen, Girardi et al. 1964). The SV40 
genome can produce T antigen but it cannot replicate its genome (Gluzman 1981).  There are 
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two different types of Cos cells which are Cos-1 and Cos-7.  They are used because they are 
easily transfected and can produce recombinant proteins for studies in biology.   
Research Focus:  Overall, the goal of LXR research is to explore a mechanism which will allow 
LXRs to be used as therapeutic targets for metabolic disorders.  However, possible side effects 
may arise and can possibly be avoided if LXRs are characterized more extensively to promote 
selective activation of genes.  This could be achieved by selective activation of an LXR isoform.  
Specifically, our lab studies LXR istoype selectivity which includes selective protein-protein 
interactions.  In this document, we will show that 14-3-3ζ binds to LXRβ not LXRα, the region 
that 14-3-3ζ binds to LXRβ, how this interaction may affect the ability of LXRβ to bind to DNA, 
the effect that 14-3-3ζ has on LXR regulated genes, and how nuclear export of LXRs requires 















MATERIALS AND METHODS 
2.1 Cells and Expression Constructs 
 Cyan fluorescent protein tagged (CFP)-LXRα, CFP-LXR , and CFP-RXR were 
obtained, generated, and verified as described earlier (Prufer, Racz et al. 2000; Prüfer 2007).  
The C-terminal truncated LXR   mutants were created using QuikChange site directed 
mutagenesis kit (Stratagene, La Jolla, CA).  We inserted stop codons into the LXR  sequence to 
replace the codons encoding either amino acid 106 or 156, creating truncated LXR  containing 
either the first 105 amino acids (105CFP- LXR  ) or the first 155 amino acids (155CFP- LXR ).  
In all constructs the mutations were verified by DNA sequencing (ABIPrism, Applied 
Biosystems,CA). Also, we cloned the coding sequences of 14-3-3ζ (Harvard Institute of 
Proteomics, MA), LXRα, and LXR  into a vector for E. coli expression with an N-terminal 
glutathione S transferase (GST) fusion (pDEST 15, Invitrogen, Carlsbad, CA) using TOPO 
cloning and the Gateway system (Invitrogen, Carlsbad, CA). We expressed GST-fusion proteins 
in E. coli and extracted them according to the manufacturer‟s instructions (Invitrogen, Carlsbad, 
CA).  In addition, we cloned the coding sequence of 14-3-3ζ into both the pDNR-CMV and the 
CFP vector using the In-Fusion system (Clontech, Mountain View, CA). 
Cos-7 and human embryonic kidney (HEK)293 cells were obtained from ATCC (Manassas, 
VA) and grown as described previously (Prufer, Racz et al. 2000; Prüfer 2007). Briefly, cell 
cultures were maintained in DMEM (Invitrogen, Carlsbad, CA) supplemented with 10% fetal 
bovine serum (FBS, Hyclone, Logan, UT), 2 mM glutamine (Invitrogen, Carlsbad, CA), and 0.1 




2.2 Expression and Purification of Proteins 
 Glutathione S transferase tagged (GST)-LXRα, GST-LXRβ, GST-14-3-3ζ (GST fusion 
proteins) and GST were expressed in BL21 E. coli. The bacterial pellets were lysed in lysis 
buffer [1mg/ml of lysozyme in buffer A (20mM HEPES, pH 7.9, 1mM EDTA, 0.5% Nonidet P-
40, 0.1% bovine serum albumin, 10% glycerol) ,supplemented with protease inhibitors and 
dithiothreitol (Yasmin, Williams et al. 2005) and phosphatase inhibitors (1mM sodium vanadate 
and 1mM sodium molybdate)].  Cells were lysed by multiple freeze-thaw cycles followed by 
sonication. Then, samples of the lysates were run on a 7.5% SDS-PAGE gel together with a BSA 
standard.  The amount of expressed GST fusion proteins was estimated, and approximately 
30 µg GST fusion proteins/experiment were bound to glutathione agarose beads.   
2.3 In vitro Binding Assay 
HEK293 cells were transfected with CFP-LXRα, wild-type and C-terminal truncated CFP-
LXRβ, and CFP-14-3-3ζ using Lipofectamine 2000 (Invitrogen, Carlsbad, CA). After 24 hours, 
the cells were scraped, washed with cold phosphate buffer saline (PBS), resuspended in 
supplemented buffer A (Yasmin, Williams et al. 2005), and subjected to one freeze/thaw cycle. 
The presence of expressed protein in the supernatants was verified by Western Blot analysis with 
the GFP monoclonal
 
antibody, JL-8 (Clontech, Mountain View, CA). 
Cell extracts containing CFP-LXRα, wild-type CFP-LXRβ or truncated CFP-LXRβ were 
combined with either GST-14-3-3ζ to test interaction or with GST to serve as a negative control. 
Cell extracts containing CFP-14-3-3ζ were combined with GST, GST-LXRα, or GST-LXRβ. All 
GST pull downs were rotated for three hours at 4°C, washed three times with supplemented 
buffer A (Yasmin, Williams et al. 2005), and then subjected to Western Blot analysis with the 




2.4 Transactivation Assays  
Cos-7 cells were subcultured into 96-well plates (Nalge Nunc Int., Naperville, IL). 
Transcriptional activities of LXRα and LXRβ with and without 14-3-3  were tested by co-
transfection experiments. In all experiments the amount of DNA transfected was normalized by 
co-transfection of an empty vector (pDNR-CMV, Clontech). Cells were transfected with 
combinations of expression plasmids (0.5 g /8 wells), LXRE luciferase reporter (0.5 g /8 
wells; gift from Dr. Auwerx, CNRS/LGME-INSERM, Illkirch, France), and the Renilla-
luciferase control plasmid pHRLTK (Promega; 0.1 g /8 wells) using Lipofectamine 2000 
reagents (Invitrogen, Carlsbad, CA).  Six hours after transfection, media was changed to media 
containing 5% FBS without lipoproteins (Intracel, Frederick, MD) to deplete cells of LXR 
ligands. Cells were treated with either vehicle (0.1% DMSO and 0.1% ethanol) or 0.1 μM 9-cis 
retinoic acid combined with 1 μM T090317 (EMD, San Diego, CA) 24 h after transfection.  
Twenty-four hours after treatment, cells were lysed on the culture plate using passive 
lysis buffer (Promega, Madison, WI), after which the samples were frozen and thawed for better 
lysis. Luciferase activities were measured using Dual-Luciferase assay reagents (Promega, 
Madison, WI) in a Fluostar Optima with two injectors (BMG Labtech, Offenburg Germany). 
Luminescence data were normalized to Renilla luciferase values and expressed as fold induction 
relative to vehicle-treated controls. Data are average from 8 data points and are presented as the 
mean 1 S.E. 
2.5 Electrophoretic Mobility Shift Assay (EMSA) 
We used histidine-tagged LXRβ and RXR for the EMSA. The oligos contained the 
LXRE sequence in the ABCA1 promoter (MWG Biotech, High Point, NC): 
Forward: 5‟GATCTTTTGACCGATAGTAACCTCTGCGCG 3‟; 




The oligos were annealed and then end-labeled with biotin.  In the binding reactions, 500ng of 
each purified protein was used together with 2 pM biotinylated oligos. In samples where LXRs 
and RXR are present, LXR and RXR were mixed in a 1:1 ratio and allowed to dimerize for 10 
min prior to use. The binding reactions were incubated at room temperature for 20 min along 
with GST and GST-14-3-3ζ. The binding reactions were loaded and electrophoresed on a pre-
cast 5% polyacrylamide TBE gel (Bio-Rad, Hercules,CA) and then transferred to a Biodyne B 
Pre-cut modified nylon membranes, 0.45µm (Pierce Biotechnology, Thermo Scientific, 
Rockford, IL).  The membrane was incubated following the Light Shift Chemiluminescent 
EMSA Kit protocol (Pierce Biotechnology, Thermo Scientific, Rockford, IL). 
2.6 Microscopy 
Cos-7 cells were plated on chambered cover glasses (Nalge Nunc Int., Naperville, IL) and 
transfected with either YFP-LXRβ or CFP-14-3-3ζ using Lipofectamine 2000 (Invitrogen, 
Carlsbad, CA).  After transient transfections, cells were used for microscopy within 48 h.  For 
imaging experiments, cells expressing YFP-LXRβ or CFP-14-3-3ζ either alone or together were 
cultured for 18 h in media containing 5% FBS without lipoproteins (Intracel, Frederick, MD) 
prior to the experiment to deplete cells of the ligands for LXR. For a subset of imaging 
experiments, cells were treated with vehicle (0.2% DMSO) or a combination of 100nM 9-cis-
retinoic acid (Sigma, St. Louis, MO) and 1mM T09 (EMD, San Diego, CA) along with either 
1mM 12-O-tetradecanoylphorbol-13-acetate (TPA, a protein kinase C activator) or 100mM 
forskolin (a protein kinase A activator) for 24 hours after transfection.   
 Images were collected from an Olympus IX81 fluorescence microscope using a 40×/0.6 
NA objective and a digital CCD camera (Hamamatsu Photonics, Japan). The Yellow GFP BP 
filter (exciter: HQ500/20, emitter HQ535/30, beamsplitter Q515Ip; Chroma Technology Corp, 
Rockingham,VT) was used for detection of YFP.  The Cyan GFP v2 filter (exciter: D436/20, 
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emitter D480/40, beamsplitter 455dcIp; Chroma Technology Corp.) was used for detection of 
CFP. Nuclear and cytoplasmic fluorescence intensities were measured using IPLab software 
(Scanalytics Inc., Fairfax, VA) in each 50–100 cells expressing either YFP-LXRβ or CFP-14-3-
3ζ either alone or in combination with each other. Cells were randomly chosen by imaging 
several areas of fluorescing cells.  
2.7 Permeabilization Experiments 
Nuclear export assays were performed as described previously (Prufer and Barsony 
2002).  HEK293 cells were plated onto chamber slides coated with gelatin.  Twenty-four hours 
later the cells were transfected with plasmids expressing either YFP-LXRα or YFP-LXRβ using 
Lipofectamine 2000 (Invitrogen, Carlsbad, CA).  Twenty-four hours after transfection, cells were 
treated with vehicle (0.2% DMSO), leptomycin B, or antagonist (1µM geranyl geranyl 
pyrophosphate (ggPP, Sigma, St. Louis, MO) for one hour at 37°C.  The above treatments were 
present both during permeabilization, during washing steps and for one hour at 37°C (or 4°C as 
indicated) after permeabilization.  Transport buffer (TB) contained both protease inhibitors and 
cyclohexamide.  Rabbit reticulocyte lysate was added to the TB where indicated.  Cells in one 
chamber were treated for 10 minutes on ice with TB containing 50ug/mL digitonin.  Nuclear and 
cytoplasmic fluorescence intensities were measured using IPLab software (Scanalytics Inc., 
Fairfax, VA) in each 50–100 cells expressing either YFP-LXRβ or CFP-14-3-3ζ either alone or 









14-3-3  INTERACTS WITH LIVER X RECEPTOR  BUT NOT LIVER X RECEPTOR  
3.1 Introduction 
Liver X Receptors (LXRs) are transcription factors that belong to the Type II Nuclear 
Receptor family.  These receptors include two subtypes, LXR  and LXR , which are activated 
by oxysterols (Willy, Umesono et al. 1995; Janowski, Willy et al. 1996; Peet, Janowski et al. 
1998).  LXRs regulate transcription of genes for proteins that play key roles in cholesterol 
metabolism and transport such as the ATP-binding cassette (ABC) A1 transporter 
(Venkateswaran, Laffitte et al. 2000; Chawla, Boisvert et al. 2001), and for lipogenesis such as 
the steroid response element binding protein (SREBP)-1c (Repa, Liang et al. 2000; Cagen, Deng 
et al. 2005). LXRs regulate cholesterol transport in the liver and macrophages, and under normal 
circumstances prevent atherosclerosis (Repa and Mangelsdorf 2002; Tangirala, Bischoff et al. 
2002; Terasaka, Hiroshima et al. 2003; Crestani, De Fabiani et al. 2004). Synthetic LXR ligands 
could be used to treat diseases such as atherosclerosis (Terasaka, Hiroshima et al. 2003), but their 
lipogenic effect in the liver causes hypertriglyceridemia (Plosch, Kok et al. 2002).  LXR  and 
LXR  share 78% identity in DNA and ligand-binding domains.  LXR  is expressed at high 
levels in liver, intestine, adipose tissue, and macrophages (Willy, Umesono et al. 1995), whereas 
LXR  is expressed ubiquitously (Teboul, Enmark et al. 1995).  Knock-out studies have shown 
that LXRβ more effectively activates genes in peripheral cells, such as macrophages, than in the 
liver (Quinet, Savio et al. 2006).  The mechanism of this tissue and LXR-isotype selectivity is 




 The 14-3-3 proteins are a highly conserved family that regulates intracellular signal 
transduction events within all eukaryotic cells.  These 30kDa α-helical molecules consist of 
seven isotypes (β, γ, ε, ζ, δ, η, and ε) in mammals, 15 isoforms in Arabidopsis and two each in 
Drosophila melanogaster and Caenorhabditis elegans (Rittinger, Budman et al. 1999; Fu, 
Subramanian et al. 2000; Tzivion, Shen et al. 2001).  Dimeric 14-3-3 proteins are ubiquitously 
expressed and play a role in a wide variety of signal transduction pathways including, the MAPK 
pathway.  Raf links activated cell surface receptors to the classical mitogen-activated protein 
kinase pathway (MAPK), extracellular signal-regulated kinase (ERK) 1 and 2, and MAPK/ERK.  
Mitotic phosphatase Cdc25C/B regulates entry from G2 into mitosis and apoptosis through the 
BH3 domain-only pro-apoptotic protein (Fanger, Widmann et al. 1998; Rittinger, Budman et al. 
1999; Fu, Subramanian et al. 2000; Tzivion, Shen et al. 2001).  14-3-3 participates in regulating 
the subcellular localization and function of both Raf and Cdc25C/B (Brunet, Kanai et al. 2002).   
 14-3-3 regulates cellular processes by modulating protein localization (Muslin, Tanner et 
al. 1996).   In most cases, 14-3-3 binding sequesters the phosphorylated target protein in a 
particular subcellular compartment, and dephosphorylation of the target protein releases it from 
14-3-3 and makes it available to signaling pathways.  This mechanism of regulation contributes 
to the nuclear retention of proteins including human telomerase reverse transcriptase (TERT), 
thioredoxin-like protein 2 (Txl-2), and checkpoint kinase (Chk1) (Tang, Suen et al. 1998; 
Seimiya, Sawada et al. 2000; Jiang, Pereira et al. 2003). 
 14-3-3 proteins interact with target proteins that are phosphorylated but they can bind to 
those that are not phosphorylated as well.  14-3-3 proteins form homodimeric and heterodimeric 
cup-shaped structures (Liu, Bienkowska et al. 1995; Xiao, Smerdon et al. 1995).  These 
structures allow 14-3-3 proteins to bind to a large number of phosphorylated proteins through 
one or more short phosphoserine/threonine containing sequence motifs in target proteins 
29 
 
(Muslin, Tanner et al. 1996; Yaffe, Rittinger et al. 1997).  14-3-3 proteins recognize the 
sequences R (S/Ar)XpSXP and R X(Ar/S)XpSXP, in which „Ar‟ denotes an aromatic residue 
(Yaffe, Rittinger et al. 1997).  However, a few of the 14-3-3 binding peptides have been shown 
with sequences that deviate from these motifs or do not require phosphorylation.  For example, 
binding of 14-3-3 to proteins like R18, a Raf derived peptide  (Fu, Subramanian et al. 2000), and 
carbohydrate response element-binding protein (ChREBP) does not require a phosphorylated 
residue (Li, Chen et al. 2008). 
  14-3-3 , also known as stratifin, has been widely studied because of its affiliation with 
cancer (Hermeking 2003).  14-3-3  is a target gene of p53 and upregulation 14-3-3  leads to cell 
cycle arrest (Hermeking, Lengauer et al. 1997).  Also, it has been shown that 14-3-3  interacts 
with members of the nuclear receptor super-family, the glucocorticoid receptor (GR)  and the 
androgen receptor (AR) (Widen, Zilliacus et al. 2000; Quayle and Sadar 2007).  14-3-3  was 
shown to increase the transcriptional activity of AR in the absence of ligand and act as a negative 
regulator of GR  signaling (Widen, Zilliacus et al. 2000; Kino, Souvatzoglou et al. 2003).  
These data together led us to hypothesize that interaction of 14-3-3  with LXRs may play a role 
in functions of LXRs.  Therefore, we explored whether 14-3-3  interacts with and affects the 
functions of LXR  and LXR .  
3.2 Results 
3.2.1 14-3-3  Interacts with LXRβ but Not with LXRα 
14-3-3  was shown to interact with AR and GR (Widen, Zilliacus et al. 2000; Kino, 
Souvatzoglou et al. 2003).  Since AR and GR are nuclear receptors similar to LXRs, we 
hypothesized that 14-3-3  may also interact with LXRα and/or LXRβ.  We performed GST 
pulldown assays where either GST, GST-LXR , or GST-LXR  was incubated with extracts 
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from HEK 293 cells expressing CFP-14-3-3  to determine if 14-3-3  interacts with the LXRs.  
The expression of similar amounts of GST, GST-LXR , GST-LXR , and GST-14-3-3  was 
verified using Western blot analysis (Figure 3.1).  We found that GST-LXRβ but not GST-LXRα  
interacts with CFP-14-3-3  (Figure 3.2).  As a positive control, we included extracts from cells 
expressing CFP-RXR, a known binding partner of both LXRα and LXRβ, and incubated these 
extracts with GST, GST-LXR , or GST-LXR .  We found that both GST-LXRα and GST-
LXRβ interact with CFP-RXR as expected (Figure 3.3).  As a negative control, we included 
extracts from cells overexpressing CFP, which did not bind GST-LXRα and GST-LXRβ (data 
not shown).  These data show that 14-3-3  interacts with LXRβ but not LXRα.  To confirm that  
 
 
Figure 3.1 GST, GST 14-3-3ζ, GST-LXRα, and GST-LXRβ are being expressed in E.coli.  
Extracts from bacterial cells expressing GST, GST 14-3-3ζ, GST-LXRα, and GST-LXRβ were 






Figure 3.2 LXRβ but not LXRα interacts with 14-3-3  
GST constructs were expressed, purified, and bound to glutathione agarose beads (Sigma, St. 
Louis, MO) at 30 μg/μl beads using standard methods.  HEK293 cells were transfected with 
CFP-14-3-3ζ, using Lipofectamine 2000 (Invitrogen, Carlsbad, CA).  Cells were lysed in the 
presence of phosphatase inhibitors. The GST pull down assays were performed as described 
previously (Yasmin, Williams et al. 2005) in the presence of phosphatase inhibitors. After 3 hour 
incubation at 4ºC, beads were washed and denatured in sample buffer containing 5% 
mercaptoethanol. Samples were separated using SDS-PAGE, and membranes were 
immunoblotted with GFP antibody (JL-8, Clontech).  Lane 1: GST- LXR  with CFP-14-3-3ζ; 
Lane 2: GST-LXRα with CFP-14-3-3ζ; Lane 3: GST control with CFP-14-3-3ζ; Lane 4: input 




Figure 3.3 LXRα and LXRβ interact with RXR 
GST constructs were expressed, purified, and bound to glutathione agarose beads (Sigma, St. 
Louis, MO) at 30 μg protein/μl beads using standard methods.  HEK293 cells were transfected 
with CFP-RXR using Lipofectamine 2000 (Invitrogen, Carlsbad, CA).  Cells were lysed in the 
presence of phosphatase inhibitors. The GST pull down assays were performed as described 
previously (Yasmin, Williams et al. 2005) in the presence of phosphatase inhibitors. After 3 hour 
incubation at 4ºC, beads were washed and denatured in sample buffer containing 5% 
mercaptoethanol. Samples were separated using SDS-PAGE, and membranes were 
immunoblotted with GFP antibody (JL-8, Clontech). Lane 1: GST-LXRα with CFP-RXR; Lane 
2: GST-LXRβ with CFP-RXR; Lane 3: GST control with CFP-RXR; Lane 4: CFP-RXR input 
(10%). 
 
14-3-3  interacts with LXRβ, we incubated GST-14-3-3  together with extracts from cells 
expressing CFP-LXR . We found that GST-14-3-3  interacts with CFP-LXRβ (Figure 3.4) 
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3.2.2 14-3-3σ Binds LXR  in the DNA Binding Domain but 14-3-3σ Does Not Affect LXR  
Binding to DNA 
 
To further explore the interaction between 14-3-3ζ and LXRβ, we next determined the 
region within LXRβ that is important for interaction with 14-3-3ζ.  We tested binding of extracts 
from HEK 293 cells expressiong various C-terminally truncated CFP-LXRβ to GST-14-3-3  
using GST pulldown assays. Whereas all LXRβ containing the first 155 amino acids (155CFP- 
LXRβ) bound GST-14-3-3 , LXRβ containing the first 105 amino acids (105CFP- LXRβ) did 
not (Figure 3.6). These data show that amino acids 106 to 155 within LXRβ are important for the 
interaction with 14-3-3 .  Since 14-3-3  binds LXR  in the DBD (Figure 3.5), we next 





Figure 3.4 LXRβ interacts with 14-3-3 GST constructs were expressed, purified, and bound to 
glutathione agarose beads (Sigma, St. Louis, MO) at 30 μg protein/μl beads using standard 
methods.  HEK293 cells were transfected with CFP-LXRβ using Lipofectamine 2000 
(Invitrogen, Carlsbad, CA).  Cells were lysed in the presence of phosphatase inhibitors. The GST 
pull down assays were performed as described previously (Yasmin, Williams et al. 2005) in the 
presence of phosphatase inhibitors. After 3 hour incubation at 4ºC, beads were washed and 
denatured in sample buffer containing 5% mercaptoethanol. Samples were separated using SDS-
PAGE, and membranes were immunoblotted with GFP antibody (JL-8, Clontech).  Lane 1: GST 
control with CFP-LXR ; Lane 2: GST-14-3-3ζ with CFP-LXR ; Lane 3: empty; Lane 4: CFP-






Figure 3.5 Schematic presentations of C-terminal truncations of LXRβ  
performed an Electrophoretic Mobility Shift Assay (EMSA) using a probe encoding an LXR 
response element within the promoter region of the ABCA1 gene.  Purified His-LXR  was 
incubated in the presence of purified His-RXR along with various concentrations of GST-14-3-
3 .  GST alone was used in the same concentrations as GST-14-3-3  as a control.  Figure 3.7 
show that His-LXR  bound the probe in the presence of His-RXR independently of the 
concentration of 14-3-3 .  We conclude that 14-3-3  does not affect binding of LXR  to DNA. 
3.2.3 14-3-3σ Decreases Both the Basal and the Ligand-induced Transcriptional Activity of 
LXR   
14-3-3  was shown to increase the transcriptional activity of AR in the absence of ligand    
and act as a negative regulator of GR  signaling (Widen, Zilliacus et al. 2000; Kino, 
Souvatzoglou et al. 2003).  We hypothesized that 14-3-3  has an effect on the function of LXRβ. 
Therefore we tested dose dependence of the effect of 14-3-3  on the transcriptional activity of 
LXRβ. We transfected Cos-7 cells with various ratios of LXRβ to 14-3-3  expression plasmids 
and found a dose-dependent effect of 14-3-3  on both the basal and the ligand-induced 
transcriptional activity of LXRβ (Figure 3.8). Whereas ligand induced the transcriptional activity 




Figure 3.6 155CFP-LXR  but not 105CFP-LXR  binds 14-3-3ζ 
GST-14-3-3ζ and cell extracts were prepared and GST pull downs were performed Figure 3.2. 
The C-terminal truncated LXRβ contain either the first 105 amino acids of LXRβ (105CFP-
LXRβ) or the first 155 amino acids of LXRβ (155CFP- LXRβ). Lane 1: GST control with 
155CFP-LXRβ; Lane 2: GST-14-3-3ζ with 155CFP-LXRβ Lane 3: GST control with CFP-
LXR ; Lane 4: GST-14-3-3ζ with CFP-LXRβ; Lane 5: GST control with 105CFP-LXR ; Lane 
6: GST-14-3-3ζ with CFP-105LXRβ; Lane 7: CFP-LXRβ input (5%); Lane 8: 155CFP-LXRβ 
input (5%); Lane 9: 105CFP-LXRβ input (5%). 
 
ratios of LXRβ:14-3-3 ), both the basal and the ligand induced transcriptional activities of 
LXRβ were inhibited by 14-3-3  in a dose-dependent manner.  These demonstrate a specific 
effect of 14-3-3ζ on the function of LXRβ. 
3.3 Discussion  
The most important finding of this work is that 14-3-3ζ selectively interacts with LXRβ 
but not with LXRα. This result may explain some of the functional differences between the two 
LXR isotypes.  Knockout of LXRα but not of LXRβ causes fatty liver in mice on a high 
cholesterol diet (Peet, Janowski et al. 1998).  LXRα and LXRβ bind the same ligands and bind to 
the same promoter DNA sequences. Therefore, the functional dominance of LXRα is likely 
regulated by differences between the LXR isotypes in yet unidentified mechanisms.  One of 
these mechanisms may be related to the inhibitory effect of 14-3-3  on the ligand-induced 
transcriptional activity of LXRβ.  It is likely that, selective protein-protein interactions regulate 
the functions of LXRα and LXRβ.  Another example of isotype-selective interaction of 14-3-3  
35 
 
has been shown, previously, for two GR isotypes, GRα and GRβ (Kino, Souvatzoglou et al. 
2003).  Whereas 14-3-3 interacts with GRα it does not interact with GRβ.  Such selective 
interactions of 14-3-3ζ with both LXR and GR isotypes may explain functional differences of 
otherwise very similar receptor isotypes.   
Phosphorylation may not play a role in the interactions of 14-3-3ζ and LXRβ.  Whereas 
both forskolin and 12-O-tetradecanoylphorbol-13-acetate (TPA), known activators of PKA and  
PKC respectively, inhibit the functions of LXRα (Delvecchio, Bilan et al. 2007; Yamamoto, 
Shimano et al. 2007), we found that forskolin had no effect on LXRβ transcriptional activity.  
 
Figure 3.7 14-3-3ζ does not affect LXRβ binding to DNA 
Demonstration of LXRβ-DNA interaction between LXRβ and increasing amounts of 14-3-3ζ by 
Electromobility Shift Assay (EMSA).  The EMSA was performed using the LXR response 
element of the ABCA1 promoter as the probe along with His-LXRβ with various concentration 




There was no additional effect of these activators on the 14-3-3ζ induced inhibition of 
LXRβ transcriptional activity (Figure 3.9).  No apparent 14-3-3 binding sequence motif is 
present in LXRβ.  Other examples for phosphorylation-independent interactions of 14-3-3  
proteins are interactions with  R18, a Raf derived peptide (Fu, Subramanian et al. 2000), and 
carbohydrate response element-binding protein (ChREBP) (Li, Chen et al. 2008). 
We found that 14-3-3ζ inhibits both basal and ligand-induced transcriptional activity of 
LXRβ; the fold-induction by ligand was only slightly affected.  In contrast, 14-3-3ζ inhibits only 
the ligand-induced transcriptional activity of GRα. That can be explained by the fact that 14-3-3ζ 
 
interacts in a partial ligand-dependent fashion with the ligand binding domain of GRα 
 
 
Figure 3.8 14-3-3ζ decreases the transcriptional activity of LXR  
Cos-7 cells were transfected with LXRE luciferase reporter and the Renilla-luciferase control 
plasmid together with LXR  expression plasmid together with various ratios of LXR  and 14-3-
3ζ. Cls were treated with a combination of DMSO and ethanol (light bars) or a combination of 
1μM T090317 and 100nM 9-cis retinoic acid (dark bars). Data are presented as average of 8 data 




(Kino, Souvatzoglou et al. 2003).  14-3-3 binding inhibits the interaction between forkhead box 
(FOXO) protein and target DNA by masking the ability FOXO to bind DNA (Silhan, Vacha et 
al. 2009).  In contrast, we have shown that despite the fact that 14-3-3ζ interacts with the DNA 
binding domain of LXRβ, the interaction between 14-3-3ζ and LXRβ does not impair DNA 
binding of LXRβ.  The effect of 14-3-3  on the basal transcriptional activation of LXRβ, 
therefore, is likely mediated through a ligand-independent interaction of 14-3-3ζ with the DNA 
binding domain of LXRβ.  This interaction may also be indirect, since we used cell extracts to 
explore the interactions between LXRβ and 14-3-3ζ. 14-3-3 proteins are known to regulate 
cellular processes by modulating their target protein‟s localization.  For example, 14-3-3ζ 




Figure 3.9 PKA or PKC activators had no affect on the transcriptional activity of LXRβ with or 
without 14-3-3. Cos-7 cells were transfected with LXRE luciferase reporter and the Renilla-
luciferase control plasmid together with LXR .  Cells were treated for 24 hours with either 
ethanol (V, vehicle) or 1μM T090317 and 100nM 9-cis retinoic acid (A, agonist), combined with 
either DMSO (light bars), forskolin (100nM; gray bars), a protein kinase A (PKA) activator, or 
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12-O-tetradecanoylphorbol-13-acetate (TPA; 1nM; dark bars), a protein kinase C (PKC) 
activator.  Data are presented as average of 8 data points‟ ±1S.E. 
found that 14-3-3ζ did not affect the localization of LXRβ in the presence or absence of PKA 
and PKC activators (Figure 3.10).  These data further support an unconventional mechanism by 
which 14-3-3ζ interacts with and affects the functions of LXRβ. 
3.5 Conclusion 
In summary, our results show that 14-3-3ζ decreases both the basal and the ligand-
induced transcriptional activity of LXR  but not of LXRα.  This interaction between 14-3-3ζ 
and LXR  requires the DNA binding domain of LXRβ but it does not affect LXR  binding to 
DNA.  Further studies are needed to test the functional importance of these findings.  
       





























































Figure 3.10 14-3-3ζ did not affect the localization of LXR  
Cos-7 cells were transfected with YFP- LXRβ and/ or CFP-14-3-3ζ.  YFP- LXR  and CFP-14-
3-3ζ were transfected separately (A) then co-localization was observed using YFP- LXRβ with 
CFP-14-3-3ζ (B), YFP- LXRβ with CFP-14-3-3ζ along with forskolin (100nM), a protein kinase 
A (PKA) activator (C), and , YFP- LXRβ with CFP-14-3-3ζ along with12-O-











THE MECHANISM OF NUCLEAR EXPORT OF LIVER X RECEPTOR  AND LIVER 
X RECEPTOR  REQUIRES ENERGY AND IS CRM-1 INDEPENDENT 
 
4.1 Introduction 
Liver X receptors are transcription factors that belong to a superfamily of nuclear 
receptors which regulate cholesterol metabolism.  Nuclear receptors are known to shuttle 
between the cytoplasmic and nuclear compartments (Gorlich and Kutay 1999; Nonclercq, Journe 
et al. 2007; Grespin, Bonamy et al. 2008). Nuclear receptors localization is controlled by their 
interactions with the nuclear import and export machinery.  Transport of nuclear receptors can be 
either energy dependent or energy independent.  
4.2 Results 
We have previously shown that unliganded and ligand-bound LXRα and LXRβ are slowly 
exported from the nucleus; but while in the presence of the LXR anatagonist, geranyl geranyl 
pyrophosphate (ggPP), there was faster nuclear export of LXRs (Prufer and Boudreaux 2007).  
Therefore, we performed digitonin permeabilization experiments using ggPP to further explore 
the mechanism of nuclear export of LXR  and LXR .  In these experiments, the cell membrane 
is permeablized using digitonin permeabilization assays but the nuclear membrane remains intact 
(Prufer and Barsony 2002).  After permeablization of the cell membrane, the presence of 
cytoplasmic components is lost but these components are added in digtonin permeablization 
experiments using rabbit reticulocyte lysate (RRL). 
We duplicated the results that LXRα and LXRβ are quickly exported out of the nucleus in the 
presence of ggPP (Figure 4.1 and Figure 4.2; top panel).  Next, we wanted to determine whether 
nuclear export of LXRα and LXRβ requires energy.  In order to determine whether export of 
LXRα and LXRβ requires energy, we used HEK293 cells expressing YFP-LXRα or YFP-LXRβ 
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in transport buffer (TB) with RRL that were pretreated with ggpP.  At 4°C nuclear export was 
slow while at 37°C nuclear export was increased (Figure 4.1 and Figure 4.2; middle panel).  . 
In addition to these findings, we wanted to determine whether LXRα and LXRβ are exported 
from nucleus by crm-1, we performed digitonin permeablization assays at 37°C in the presence 
of RRL, and leptomycin B (2nM; LMB), an inhibitor of export receptor Crm-1 (Kudo, 
Matsumori et al. 1999).  We found that both LXRα and LXRβ were not exported from the 
nucleus (Figure 4.1 and Figure 4.2; bottom panel). 
4.3 Discussion 
We have shown that nuclear export of LXR  and LXR  are energy-dependent but neither are 
Crm-1 dependent.  In addition to these findings, we found that calreticulin plays a role in the 
regulation of nuclear localization of LXRs in a ligand-dependent manner .  These findings 
indicate that LXRs are exported from the nucleus in the presence of LMB and the absence of 
RRL.  Together these data indicate that LXRs are exported in the presence of ggPP and 
calreticulin but their localization is unchanged due to LXRs being re-imported in the nucleus 






Figure 4.1 Nuclear export of LXRα requires energy but not Crm-1 
Digitonin permeablization experiments were performed in the presence of ggPP or LMB at  
37°C or 4°C.  HEK293 cells expressing YFP-LXRα were incubated for 1 hour in the presence of 
geranyl geranyl pyrophosphate (ggPP; 1µM) and/or leptomycin B (LMB; 2nM) as indicated after 





Figure 4.2 Nuclear export of LXRβ requires energy but not Crm-1 
Digitonin permeablization experiments were performed in the presence of ggPP or LMB at  
37°C or 4°C.  HEK293 cells expressing YFP-LXRβ were incubated for 1 hour in the presence of 
geranyl geranyl pyrophosphate (ggPP; 1µM) and/or leptomycin B (LMB; 2nM) as indicated after 
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